ASX Announcements

Apr 21, 2022

Kazia's paxalisib Phase II trial achieves completion

Apr 8, 2022

Kazia presents on EVT801 at AACR

Apr 8, 2022

Kazia presents preclinical data for paxalisib at AACR

Apr 6, 2022

Kazia response to SEC comments letter

Mar 21, 2022

Kazia to present at two conferences

Mar 2, 2022

Change in substantial holding

Feb 28, 2022

First patient into Cornell keto study

Feb 23, 2022

Kazia Half Year Accounts and Appx 4D

Feb 1, 2022

Notification regarding unquoted securities - KZA

Jan 31, 2022

Quarterly Activities/Appendix 4C Cash Flow Report